FENNEC PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.21 USD | +0.55% |
|
-1.39% | -17.91% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 129.1 | 192.3 | 114.4 | 252.1 | 302.9 | 249.6 | - | - |
| Enterprise Value (EV) 1 | 129.1 | 192.3 | 114.4 | 252.1 | 302.9 | 249.6 | 249.6 | 249.6 |
| P/E ratio | -10.1 x | -9.8 x | -6.57 x | -10.7 x | -18.7 x | 44.2 x | 9.89 x | 4.45 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 1,131 x | - | 164 x | 14.3 x | 4.99 x | 3.51 x | 2.64 x |
| EV / Revenue | - | 1,131 x | - | 164 x | 14.3 x | 4.99 x | 3.51 x | 2.64 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | -17.7 x | 28.4 x | 7.51 x | 7.51 x |
| FCF Yield | - | - | - | - | -5.66% | 3.53% | 13.3% | 13.3% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 19,896 | 25,810 | 26,007 | 26,261 | 26,994 | 27,105 | - | - |
| Reference price 2 | 6.490 | 7.450 | 4.400 | 9.600 | 11.22 | 9.210 | 9.210 | 9.210 |
| Announcement Date | 2/14/20 | 3/30/21 | 2/28/22 | 3/29/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.17 | - | 1.535 | 21.25 | 50 | 71.15 | 94.56 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -13.01 | -17.88 | -17.22 | -22.59 | -12.77 | 7.772 | 28.3 | 57.77 |
| Operating Margin | - | -10,520.59% | - | -1,471.6% | -60.09% | 15.54% | 39.78% | 61.09% |
| Earnings before Tax (EBT) 1 | -12.78 | -18.11 | -17.35 | -23.71 | -12.77 | 8.856 | 29.72 | 69.59 |
| Net income 1 | -12.78 | -18.11 | -17.35 | -23.71 | -16.04 | 5.736 | 26.21 | 56.13 |
| Net margin | - | -10,652.35% | - | -1,544.89% | -75.5% | 11.47% | 36.84% | 59.36% |
| EPS 2 | -0.6400 | -0.7600 | -0.6700 | -0.9000 | -0.6000 | 0.2083 | 0.9317 | 2.070 |
| Free Cash Flow 1 | - | - | - | - | -17.14 | 8.8 | 33.25 | 33.22 |
| FCF margin | - | - | - | - | -80.67% | 17.6% | 46.73% | 35.13% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | 153.41% | 126.85% | 59.19% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/14/20 | 3/30/21 | 2/28/22 | 3/29/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 1.535 | 1.677 | 3.325 | 6.515 | 9.735 | 10.21 | 11.49 | 13.22 | 15.09 | 20.53 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.173 | -4.207 | -3.546 | -5.009 | -7.899 | -6.135 | -5.27 | -4.666 | -1.017 | -1.818 | -0.7366 | 1.339 | 3.405 | 4.899 | 16.6 |
| Operating Margin | - | - | - | - | - | -399.67% | -314.25% | -140.33% | -15.61% | -18.67% | -7.21% | 11.65% | 25.76% | 32.47% | 80.84% |
| Earnings before Tax (EBT) 1 | -4.185 | -4.427 | -3.696 | -5.072 | -8.089 | -6.857 | -6.052 | -5.444 | -1.867 | -1.818 | -1.9 | 0.8057 | 3.716 | 5.047 | 15.7 |
| Net income 1 | -4.185 | -4.427 | -3.696 | -5.072 | -8.089 | -6.857 | -6.052 | -5.444 | -1.867 | -2.682 | -1.427 | 0.6574 | 2.789 | 4.405 | 14.6 |
| Net margin | - | - | - | - | - | -446.71% | -360.88% | -163.73% | -28.66% | -27.55% | -13.97% | 5.72% | 21.1% | 29.19% | 71.1% |
| EPS 2 | -0.1600 | -0.1800 | -0.1400 | -0.1900 | -0.3100 | -0.2600 | -0.2300 | -0.2100 | -0.0700 | -0.1000 | 0.2133 | 0.0117 | 0.0867 | 0.1417 | 0.3400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 2/28/22 | 5/12/22 | 8/12/22 | 11/11/22 | 3/29/23 | 5/11/23 | 8/3/23 | 11/6/23 | 3/21/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | -17.1 | 8.8 | 33.3 | 33.2 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 2/14/20 | 3/30/21 | 2/28/22 | 3/29/23 | 3/21/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
9.21
USD
Average target price
18.33
USD
Spread / Average Target
+99.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.91% | 250M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- FENC Stock
- Financials Fennec Pharmaceuticals Inc.
